Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Latest Press Releases
Evaluate Vantage 2020 Review: Biopharma IPOs and venture financing break records; global drug stocks add half a trillion dollars in market capitalization
The top 600 biopharma firms added $487 billion in market capitalisation in 2020, according to the Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review report,…
Inova and BIO, in partnership with Evaluate, announce a new series of therapeutic-specific Virtual Partnering events for 2021
Inova and the Biotechnology Innovation Organization (BIO), in partnership with Evaluate announce the second annual series of Virtual Partnering events focused on critical…
Evaluate Vantage 2021 Preview: High hopes and valuations set the tone for biopharma
COVID-19 will continue to be a defining issue for pharma and biotech companies in 2021, but overall the sector will start the year from a position of strength, according…
Browse the archive
Small drug developers continue to hold all the cards, while young device makers suffer from a shrinking pool of buyers
Vantage releases its half-year analysis of sector performance: Pharma, Biotech and Medtech Half-Year Review 2018
Worldwide Prescription Drug Sales Accelerate To $1.2 Trillion By 2024, As Unmet Need Drives Annual Compound Growth To Over 6%
Eleventh annual EvaluatePharma World Preview 2018, Outlook to 2024 report launches at BIO 2018.
Worldwide Orphan Drug Sales Are Forecast To Grow At A Cagr Of 11.3% From 2018 To 2024, Double The Rate Forecast For The Non-Orphan Drug Market
Annual “EvaluatePharma Orphan Drug 2018 Report” sees Orphan drugs capture a fifth of worldwide prescription sales by 2024 as sales grow to $262bn.
Fast Pace Of Drug And Device Approvals In 2017 Signals Wider Sector Health For Biopharma But Medtech Companies Struggle
EP Vantage releases its annual analysis of sector performance: Pharma, Biotech and Medtech 2017 in Review.
Uptick In M&A Activity And Investor Cash Expected To Re-Invigorate Pharma And Biotech In 2018
EP Vantage’s Annual Pharma and Biotech Preview explores what’s in store for 2018.
Worldwide Medtech Sales Forecast To Reach $522 Billion By 2022 With A Cagr Of 5.1% Between 2016 And 2022
EvaluateMedTech Report Launches in Conjunction with The MedTech Conference.
Biopharma Stages A Strong Recovery Over The First Half Even As M&A Deals Disappoint, While Unprecedented Amounts Of Money Flow In Medtech But Not Towards Smaller Innovators
EP Vantage Releases Half-Year Reviews of Pharma & Biotech and Medtech Performance.
Japanese Pharmaceutical Market Set To Grow 3.3% (Cagr) Between 2017 And 2022, Significantly Lower Than The Worldwide Outlook (6.5% Cagr)
Latest growth forecasts show optimism surrounding new therapies coming to market counterbalanced by more stringent pricing policy enforcement.
Epi Analyzer: Blockbusters Out, Highly Targeted Therapies In
New Case Studies Highlight Niche Patient Population Identification and Analysis for Enhanced Portfolio Decision-making Using Evaluate’s Epi Analyzer
